17.05.2005 12:34:00
|
REMINDER/Phase Forward to Drive Industry Dialog at Annual Bio-IT World
Business Editors/High-Tech Editors/Medical Editors
BioITWorld Boston 2005
Booth 608
REMINDER
BOSTON--(BUSINESS WIRE)--May 17, 2005--Phase Forward (NASDAQ: PFWD)
Who: Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety
What: Bio-IT World 2005 Conference + Expo
When: Tuesday, May 17 through Thursday, May 19, 2005
Where: Hynes Convention Center, Boston, Massachusetts
Bio-IT World Conference + Expo demonstrates how technology is transforming life sciences throughout discovery and development processes. The event is designed for life science professionals seeking to evaluate and understand advanced solutions that generate, collect, and analyze the flood of information produced by the life sciences industry. Visionaries from the biotechnology, pharmaceutical, healthcare, academic, and government markets convene to learn how the latest tools and best practices will help revolutionize health, environment, and society.
As part of this year's conference, Phase Forward's Chairman and Founder, Paul Bleicher, M.D., Ph.D, will provide his insight and experience as part of the following panel discussions:
-- "Safety Surveillance in Clinical Trials - New Technologies to
Assess Safety"
The panel discussion will highlight ways the biopharmaceutical industry can assess the safety of products and ensure the safety of patients who use them. The session will include presentations from representatives of the pharmaceutical industry, press, and technology/service providers, followed by Q&A. The goal of this panel is to present a broad picture of key safety issues and provide clarification of the technologies available for assessing them. The panel will be moderated by Rebecca D. Kush, PhD, President, Clinical Data Interchange Standards Consortium (CDISC). Wednesday, May 18, from 10:45 AM - 11:30 AM.
-- "eClinical Vendor Panel Discussion"
Following up last year's session, Paul Bleicher will join other senior executives who will present their views on current and projected market conditions, challenges, and opportunities facing eClinical technology vendors. The panel will be moderated by Jerald S. Schindler, DrPH, Asst. VP, Global Biostatistics & Clinical Technology, Wyeth Research. Wednesday, May 18, from 1:00 PM - 2:30 PM.
Attendees are also invited to visit Phase Forward at Booth #608 to learn more about the company's clinical data management solutions.
For media inquiries, please contact Brian Gendron of SHIFT Communications at 617-681-1226.
About Phase Forward
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. The company helps pharmaceutical, biotechnology, and medical device companies bring needed drugs and therapies to market faster and more safely. Phase Forward offers proven solutions in electronic data capture (EDC), clinical data management (CDM), and adverse event reporting (AER). Phase Forward products and services have been utilized in over 10,000 clinical trials involving more than 1,000,000 clinical trial study participants at over 220 organizations worldwide including: AstraZeneca, Biogen Idec, Boston Scientific, Dana-Farber Cancer Institute, Eli Lilly, GlaxoSmithKline, Guidant, Procter & Gamble, Quintiles, Sanofi-Aventis, Schering-Plough Research Institute, and Serono. Additional information about Phase Forward is available at www.phaseforward.com.
--30--KC/bo*
CONTACT: SHIFT Communications Brian Gendron, 617-681-1226
KEYWORD: MASSACHUSETTS TRACK INDUSTRY KEYWORD: HARDWARE BIOTECHNOLOGY SOFTWARE INTERNET E-COMMERCE REMINDER TRADESHOW SOURCE: Phase Forward
Copyright Business Wire 2005
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Oracle Corp.mehr Nachrichten
28.01.25 |
NASDAQ Composite Index-Wert Oracle-Aktie: So viel Gewinn hätte ein Oracle-Investment von vor 5 Jahren abgeworfen (finanzen.at) | |
27.01.25 |
Handel in New York: S&P 500 in Rot (finanzen.at) | |
24.01.25 |
Musk kritisiert Trumps KI-Pläne - Softbank- und Oracle-Aktien schwächer (dpa-AFX) | |
22.01.25 |
Gewinne in New York: Am Nachmittag Gewinne im NASDAQ Composite (finanzen.at) | |
22.01.25 |
Optimismus in New York: NASDAQ Composite bewegt sich am Mittwochmittag im Plus (finanzen.at) | |
22.01.25 |
AKTIEN IM FOKUS 3: KI-Fantasie bei Siemens Energy, Hochtief, Oracle und mehr (dpa-AFX) | |
22.01.25 |
Aufschläge in New York: NASDAQ Composite beginnt Handel mit Gewinnen (finanzen.at) | |
22.01.25 |
AKTIEN IM FOKUS 2: Rechenzentren-Fantasie bei Siemens Energy, Hochtief & Oracle (dpa-AFX) |
Analysen zu Oracle Corp.mehr Analysen
27.01.25 | Oracle Buy | Jefferies & Company Inc. | |
03.01.25 | Oracle Sector Perform | RBC Capital Markets | |
10.12.24 | Oracle Hold | Joh. Berenberg, Gossler & Co. KG (Berenberg Bank) | |
10.12.24 | Oracle Sector Perform | RBC Capital Markets | |
10.12.24 | Oracle Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Oracle Corp. | 163,92 | -0,28% |
Indizes in diesem Artikel
NASDAQ Comp. | 19 391,96 | -1,20% |